HCV / Hepatitis

Researchers at the University of North Carolina at Chapel Hill have found out how hepatitis A causes acute liver injury.

Hepatitis A cases have been reported throughout at least nine different US states and the number of cases continue to rise.

Researchers from Nanjing Biopoint have made a breakthrough when it comes to fighting HIV through the development of a product that uses certain material when collecting blood samples that can separate the plasma from the rest of the blood, allowing the sample to be safely sent to a testing center.

Researchers from the Copenhagen University Hospital of Denmark find that individuals who are hospitalized with infections have an increased risk of suicide ideation and death; individuals infected with hepatitis and HIV or AIDS have the highest risk of suicide-related death.

The Virginia Department of Health has issued a warning stating that there is an increased risk of hepatitis A in the state of Virginia that may potentially link back to frozen strawberries sourced from Egypt.

With the assistance of funds granted by Congress, the Department of Veteran Affairs (VA) will extend new hepatitis C (HCV) treatment to all infected veterans within their healthcare system, of all stages of illness and regardless of whether or not the infection had been acquired during military service.

A hepatitis A outbreak in Hawaii has reached more than 200 cases.

In response to an increase of hepatitis C cases in Rhode Island that have resulted in hospitalizations and deaths, the Rhode Island Department of Health and the Rhode Island Public Health Institute have worked together to compose their first ever, comprehensive epidemiological report.

Collateral damage from the ongoing opioid abuse epidemic in the United States continues to plague many rural communities across the country, with recent reports suggesting it is likely behind clusters of HIV cases in these areas.

Liver fibrosis and subsequent cirrhosis result from chronic damage to the liver that is caused by most types of chronic liver disease, including chronic hepatitis C virus infection and alcohol abuse.

World Hepatitis Day aims to increase awareness and understanding of viral hepatitis. The ECDC discusses Europe’s plan to eliminate hepatitis by 2030.

The Hawaii State Department has confirmed an open investigation of the hepatitis A infection in Oahu, Hawaii.

The US Food and Drug Administration just approved a new regimen to treat the six major forms of chronic hepatitis C (HCV).

A recent study has estimated the seroprevalence of hepatitis C virus (HCV) infection to be 0.5% in the antenatal population.

Hepatitis C virus (HCV) cure when using direct-acting antiviral (DAA) agents in human immunodeficiency virus (HIV)-coinfected patients is lower in real-world settings than when patients are enrolled in clinical trials, a new study has found.

A recent study in treatment-naïve patients with chronic hepatitis C virus (HCV) infection has shown that ledipasvir/sofosbuvir (LDV/SOF) combination therapy produces similar sustained virologic response (SVR) rates in clinical trial-based studies and real-world studies.

Charitha Gowda, MD, MPH, infectious diseases physician at Penn Presbyterian Medical Center discusses the impact direct-acting antivirals have had on patients’ adherence to their drug regimen when treating hepatitis C.

Contagion™ Editorial Board member, Charitha Gowda, MD, MPH breaks down the World Health Organization hepatitis C (HCV) guidelines update, and reminds healthcare professionals to build on these guidelines to advocate for the most effective and safest treatment options for our individual patients and all patients worldwide.

Charitha Gowda, MD, MPH, Infectious diseases physician at Penn Presbyterian Medical Center explains how the treatment regimen for treating those with acute hepatitis C differs from chronic hepatitis C.

Charitha Gowda, MD, MPH, Infectious diseases physician at Penn Presbyterian Medical Center explains the process for the evaluation of hepatitis C, leading up to treatment.

Charitha Gowda, MD, MPH, discusses the current and upcoming methods to prevent hepatitis C.

The ongoing refugee crisis facing European countries as a result of conflicts in the Middle East presents a potential public health challenge to governments already struggling with the influx of hundreds of new migrants on a daily basis.

Charitha Gowda, MD, MPH, explains why we see such a high incidence of HIV / HCV coinfection.

In a recent study of 1,812 human immunodeficiency virus (HIV)-infected individuals in sub-Saharan Africa, researchers found that none of these individuals had confirmed hepatitis C virus replication.

Global pharmaceutical company, AbbVie, announced the approval of a supplemental new drug application for VIEKIRA PAK® without ribavirin in chronic hepatitis C patients with genotype 1b (HCV-1b) and compensated cirrhosis.

Charitha Gowda, MD MPH, infectious diseases physician at Penn Presbyterian Medical Center discusses the recent decision from The Department of Veterans Affairs (VA) to supply hepatitis C (HCV) treatment to all veterans, regardless of disease stage.

Researchers from the National Academies of Sciences, Engineering, and Medicine report that there is a possibility of eliminating the transmission of both Hepatitis B and C in the United States.

Charitha Gowda, MD MPH, infectious diseases physician at Penn Presbyterian Medical Center, explains the barriers to hepatitis C (HCV) treatment.

Charitha Gowda, MD MPH, infectious diseases physician at Penn Presbyterian Medical Center discusses the preferred treatment method for hepatitis C.

Charitha Gowda, MD MPH, infectious diseases physician at Penn Presbyterian Medical Center discusses the current treatment methods for hepatitis C.